Eli Lilly (LLY) Asset Writedowns and Impairment (2011 - 2012)
Eli Lilly (LLY) reported Asset Writedowns and Impairment of $221.0 million for Q4 2012, down 26.94% on a YoY basis from $302.5 million in Q1 2012, and down 26.94% quarter-over-quarter from $302.5 million in Q4 2011.
Eli Lilly (LLY) Asset Writedowns and Impairment (2011 - 2012) Analysis & Trends
Eli Lilly has reported Asset Writedowns and Impairment for 2 years, with the latest figure at $221.0 million in Q4 2012.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Gsk | 92,316,836.42 Bn | 92,316,831.46 Bn | 7.76 Bn |
| 2 | Eli Lilly | 983.57 Bn | 978.29 Bn | 16.22 Bn |
| 3 | Johnson & Johnson | 553.56 Bn | 531.50 Bn | 15.96 Bn |
| 4 | AbbVie | 383.35 Bn | 374.00 Bn | 10.78 Bn |
| 5 | Merck | 281.71 Bn | 276.06 Bn | 12.09 Bn |
| 6 | Amgen | 182.20 Bn | 170.16 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 153.71 Bn | 145.98 Bn | 5.52 Bn |
| 8 | Pfizer | 143.75 Bn | 130.98 Bn | -1.21 Bn |
| 9 | Bristol Myers Squibb | 109.71 Bn | 99.25 Bn | 8.07 Bn |
| 10 | Novartis Ag | 108.28 Bn | 107.60 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2012 | 221.00 Mn |
| Dec 31, 2012 | 221.00 Mn |
| Dec 31, 2011 | 302.50 Mn |
| Dec 31, 2011 | 302.50 Mn |